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ttp://dx.doi.org/10.1016/j.ajpath.2013.06.033Podocytes represent an essential component of the kidney’s glomerular ﬁltration barrier. They stay
attached to the glomerular basement membrane via integrin interactions that support the capillary wall
to withstand the pulsating ﬁltration pressure. Podocyte structure is maintained by a dynamic actin
cytoskeleton. Terminal differentiation is coupled with permanent exit from the cell cycle and arrest in
a postmitotic state. Postmitotic podocytes do not have an inﬁnite life span; in fact, physiologic loss in
the urine is documented. Proteinuria and other injuries accelerate podocyte loss or induce death.
Mature podocytes are unable to replicate and maintain their actin cytoskeleton simultaneously. By the
end of mitosis, cytoskeletal actin forms part of the contractile ring, rendering a round shape to
podocytes. Therefore, when podocyte mitosis is attempted, it may lead to aberrant mitosis (ie, mitotic
catastrophe). Mitotic catastrophe implies that mitotic podocytes eventually detach or die; this is
a previously unrecognized form of podocyte loss and a compensatory mechanism for podocyte hyper-
trophy that relies on posteG1-phase cell cycle arrest. In contrast, local podocyte progenitors (parietal
epithelial cells) exhibit a simple actin cytoskeleton structure and can easily undergo mitosis, supporting
podocyte regeneration. In this review we provide an appraisal of the in situ pathology of mitotic
catastrophe compared with other proposed types of podocyte death and put experimental and renal
biopsy data in a uniﬁed perspective. (Am J Pathol 2013, 183: 1364e1374; http://dx.doi.org/10.1016/
j.ajpath.2013.06.033)Supported by grant AN372/12-2 from theDeutsche Forschungsgemeinschaft
(H.J.A.) and by grant NIDDK079333 the from the O’Brien Kidney Center at
Washington University School of Medicine in St. Louis (H.L.).Podocyte injury is a key manifestation of proteinuric glo-
merulopathies, for example, minimal change disease (MCD),
focal segmental glomerulosclerosis (FSGS), and diabetic
nephropathy. Normal podocytes are postmitotic cells com-
posed of a voluminous cell body with a single well-formed
nucleus and primary and secondary foot processes attached to
adjacent capillary loops in an interdigitating manner. Injured
podocytes invariably respond with foot process effacement,
a frequently reversible process, thought to help injuredstigative Pathology.
.podocytes stay attached to the glomerular basement
membrane (GBM).1 Sustained podocyte injury, however, is
likely to cause podocyte cell detachment and/or death, which,
if extensive, leads to progressive glomerulosclerosis and end-
stage kidney disease.2 The mechanisms of podocyte loss
Mitotic Catastrophe in Podocytescould be important in three ways: ﬁrst, as a pathophysiologic
determinant of progressive chronic kidney disease; second,
as a potentially signiﬁcant histopathologic prognostic pa-
rameter; and third, as a target for novel therapies to prevent
progressive glomerulosclerosis.
Currently, podocyte assessment in human disease is often
limited to the ultrastructural appearance of the secondary foot
processes, which normally appear as teethlike, interdigitating,
and slit-membraneeforming processes, whereas damaged foot
processes appear ﬂat (effaced) under transmission electron
microscopy (EM). The speciﬁc podocyte death morphology is
not currently routinely assessed in renal biopsy specimens or
for diagnostic or glomerular disease risk assessment.
Approximately one dozen mechanisms of cell death are
described, mostly in vitro and in vivo models, suggesting
numerous avenues for podocyte loss (Table 1).14,15 These
mechanisms include apoptosis (physiologic cell death impli-
cated in organogenesis and, if defective, in disease patho-
genesis), anoikis (cell death due to absence of cell-matrix
interactions implicated in cancer metastasis), autophagy
(starvation-induced cell death), entosis (cell-in-cell death,
cannibalism), necrosis (unregulated lysis of cell membrane),
necroptosis (speciﬁcally regulated-programmed necrosis),
mitotic catastrophe (MC; cell death due to aberrant mitosis),
and others.14e16 The gold standard for detecting some forms of
cell death, for example, apoptosis, necrosis, or MC, remains
the nuclear pathologic feature viewed with EM.1 Podocyte
maturation and apoptosis were studied in experimental
animals. Defective apoptosis is thought to play a role in certain
types of nephrotic syndrome, but little is known about podo-
cyte cell death and its signiﬁcance in human podocyte dis-
ease.15e18 Several studies recently suggested that MC
represents a previously unrecognized cause of podocyte loss in
experimental models of glomerular and human disorders.3,4,19
This review is a critical appraisal of i) the current views on howTable 1 Mitotic Catastrophe and Other Types of Podocyte Death in H
Cell death
type Deﬁnition Morphologic features
Mitotic
catastrophe
Aberrant mitosis Binucleation, micronuclei, aberrant
mitotic spindles
Apoptosis Nuclear death Nuclear condensation, blebbing, nuc
fragmentation, apoptotic bodies
Autophagy Nutrient
starvatione
induced death
Autophagosomes, autophagolysosom
(transient vacuoles and RER stress
Anoikis Absence of
cell-matrix
interactions
Apoptosis induced by lack of correct
cell/ECM attachment
Entosis Cell cannibalism Cellein cell
Necrosis Cell lysis Early: cytoplasmic and nuclear edem
late: plasma membrane rupture nu
and cytoplasmic disintegration
Necroptosis Regulated
necrosis
Cell membrane rupture, oncosis, but
nuclear fragmentation into apopto
bodies
ECM, extracellular matrix; RER, respiratory exchange ratio; TGF-b, transforming
The American Journal of Pathology - ajp.amjpathol.orgthe podocyte cell proliferation machinery (cell cycle) responds
to injury, potentially leading to podocyte cell death; ii) the
possible mechanisms podocytes use in an attempt to avoid
death after injury; and iii) the in situ morphology of podocyte
cell death in human disease with emphasis on MC.
Cell Cycle from the Podocyte’s Perspective
Mature podocytes are thought to be quiescent cells arrested in
the G0 (resting) phase. Cell cycle entry involves the G1 (gap)
phase, during which cells synthesize RNA, protein, and
organelles; the S phase, during which DNA is duplicated and
cells increase in size; and theM phase (formitosis), whenDNA
and protein synthesis stops and the cell divides. Cell mitosis
includes a series of sequential events referred to as interphase,
prophase, prometaphase, metaphase, anaphase, telophase, and
cytokinesis, which describe the different stages of nuclear
membrane disintegration, mitotic spindle formation, chromatin
assembly into chromosomes, chromosome segregation, nuclear
membrane formation, and cytoplasmic division. Normal cell
cycle functions are accomplished through activation of CDKs
and speciﬁc cyclins (eg, CDK1). These phosphorylate a variety
of proteins that control the cell cycle.20,21 Important regulators
of the cell cycle are the p53 and p27 proteins, which can block
the cell cycle at distinct restriction points. For example, in the
case of DNA damage the cell activates the DNA repair
machinery before completing the cell cycle. If DNA damage is
severe, p53 is activated, leading to cell death to make sure that
cells with signiﬁcant DNA damage are deleted.
Chromosome segregation depends on structural proteins
and cell cycle regulatory complexes. Podocytes express
cyclin A, B1, and D1 and CDK inhibitors, such as p21, p27,
and p57. Ki-67, a marker of G1, S, G2, andM phase, is amply
expressed in podocyte precursors, but at the capillary loop
stage, cell cycle proteins and CDKs are altered; for example,uman and Experimental Glomerular Disease
Disease
Experimental glomerular
disease Reference
HIVAN, FSGS, MCD,
IgA, other
Adriamycin nephropathy 3,4
lear Uncertain TGF-b overexpression
in cultured podocytes
5e12
es
)
Lysosomal storage
diseases
Puromycin
aminonucleoside-
induced nephrosis
13
Unknown
Unknown
a
clear
Toxic-ischemic
and necrotizing
glomerular injury
no
tic
Unknown
growth factor b.
1365
Liapis et alKi-67, cyclin A, and cyclin B1 are reduced, and CDKs and
cyclin D1 are increased. These changes are associated with
podocyte exit from the cell cycle and are concurrent with the
formation of podocyte foot processes and expression of
podocyte-speciﬁc proteins, such as podocalyxin and WT-1
characteristic of differentiated podocytes.22,23 Mature podo-
cytes are indeed sustained by speciﬁc CDK inhibitor up-
regulation, which guarantees their highly specialized struc-
ture and function.19
Cyclins and CDKs are altered in human and experimental
podocyte injury. For example, in the cellular type of human
FSGS, studies have found absent p27, p57, and cyclin D1
expression and increased cyclin E, cyclin A, cyclin B1, CDK2,
and p21.24 In experimental Adriamycin-induced FSGS, the
CDK inhibitor p21 is increased and found to protect podocytes
in this model.25 In other glomerular diseases, such as
membranous glomerulopathy, podocytes demonstrate DNA
synthesis but no podocyte proliferation. Studies in experi-
mental membranous nephropathy report that Cdc2, cyclin B1,
and cyclin B2 are increased in rat podocytes despite absent
proliferation.26 The results suggest that increased expression
of cell cycle regulatory proteins is not sufﬁcient for podocyte
proliferation and that other factors appear to be involved. In
diabetes, a disease characterized by podocyte hypertrophy,
glomerular p21 is increased in the streptozotocin-induced
mouse model, and p21 and p27 are increased in the
glomeruli of diabetic db/db mice and Zucker diabetic rats that
develop type 2 diabetic nephropathy.Diabetic p21/mice are
protected from glomerular hypertrophy. p21/ mice develop
glomerular hyperplasia rather than hypertrophy, and progres-
sive renal failure is halted.27
In each phase of the cell cycle, the nucleus has characteristic
morphologic features, for example, in interphase when the
DNA is copied, the nucleus is visible, but chromosomes are
invisible.28 Micronuclei can also be present during interphase;
they are rounded DNA aggregates that represent genomic
instability and typically appear adjacent to the nucleus with
a diameter not larger than one-third of the nucleus. In anaphase
the mitotic spindle is visible, and new nuclear membrane
forms around the sister chromatids; ﬁnally, the cytoplasm
divides into two identical daughter cells by cytokinesis in all
cell types except for highly specialized postmitotic cells,
including podocytes. Indeed, because differentiated podocytes
have an intrinsic barrier to mitosis, a proliferative response of
surviving podocytes instead of contributing to recovery from
injury may accelerate podocyte loss and glomerulosclerosis.
However, we have previously reported that podocyte
progenitors exist in the glomerulus that can complete the cell
cycle to potentially regenerate lost podocytes.Parietal Epithelial Cells: Podocyte Progenitors
That Can Proliferate
Recently, it was demonstrated that a population of progen-
itor cells in the parietal epithelium of the Bowman capsule1366of adult human kidney acts as a source of intrarenal
progenitors for visceral podocytes.29e32 These cells exhibit
a mixed phenotype between parietal epithelial cells and
podocytes and can proliferate and differentiate generating
neopodocytes during development and in postnatal and
adolescent mice.32,33 These cells have the potential to be-
come podocytes without yet displaying the complex cyto-
skeletal structure that prohibits an efﬁcient mitotic division
(Figure 1). Indeed, during development, podocyte progeni-
tors up-regulate podocyte-speciﬁc genes and show de novo
expression of the CDK inhibitor p27; at the same time PAX2
is down-regulated as progenitors differentiate into podo-
cytes.34 The down-regulation of PAX2 by WT1 seems to be
a prerequisite for WT1-controlled differentiation35 through
inhibition of b-catenin/Wnt signaling.36 Interestingly, the
b-catenin/Wnt signaling is also a direct activator of cyclin
D1, a critical initiator of cell division that controls podocyte
progenitor proliferation during development and postnatally,
maintaining their capacity to divide while they are in an
undifferentiated state.36,37 Podocyte progenitors exhibit
a simple cytoskeleton and a high proliferative capacity,
which disappears once the highly specialized podocyte
phenotype is acquired. Notch activation triggers proliferation
of podocyte progenitors by promoting entry into the S-phase
and mitotic division.19 However, attenuation of Notch
activity is required to allow podocyte progenitors to differ-
entiate into visceral podocytes, as demonstrated by abnormal
DNA content and podocyte death by MC after impaired
down-regulation of the Notch pathway.19
The discovery that parietal epithelial cells represent
podocyte progenitors and can potentially differentiate into
podocytes provides an explanation of how podocyte
regeneration can be achieved even if differentiated podo-
cytes are virtually unable to divide successfully. Several
reports indicate that angiotensin-converting enzyme inhibi-
tors, retinoids, and steroids enhance the capacity of podo-
cyte progenitors to become podocytes.38e41 In addition,
podocyte regeneration can be modulated using Notch
inhibitors in mouse models of FSGS, directly inﬂuencing
the amount of proteinuria and the occurrence of glomer-
ulosclerosis.19 Finally, recent studies suggest that blockade
of SDF-1/CXCL12 also increases the number of podocytes
and reduces proteinuria in type 2 diabetic mice by
enhancing parietal epithelial cell differentiation toward the
podocyte phenotype,42,43 suggesting that pharmacologic
treatments can modulate podocyte progenitor proliferation
and/or differentiation into podocytes.Stressed Podocytes Reenter the Cell Cycle and
Undergo Hypertrophy but Fall Short of Mitosis
Hypertrophy (increase in cell size) and hyperplasia (increase
in cell number) are two cellular strategies to compensate for
cell stress or relative cytopenia (eg, during organogenesis or
injury). Hypertrophy and hyperplasia both imply thatajp.amjpathol.org - The American Journal of Pathology
Figure 1 Working model of the role of cell cycle in proliferation of podocyte progenitor cells or podocyte hypertrophy and how aberrant podocyte
proliferation may lead to podocyte loss. De novo podocyte generation starts from renal progenitors that are committed to the podocyte lineage within the
parietal epithelial cell (PEC) layer. On activation, PECs enter the cell cycle (ie, proliferate and differentiate), which ﬁrst creates a transitional cell that expresses
both PEC and podocyte markers. Transitional cells are often found around the vascular pole of the glomerulus. Terminal differentiation into podocytes usually
occurs only on the glomerular tuft, which implies loss of all parietal cell and progenitor markers so that these cells can no longer be distinguished from
podocytes. Only parietal cell lineage tracing experiments are able to document that these are a progeny of former parietal epithelial cells. Once terminally
differentiated (and postmitotic) podocytes are exposed to stress, such as loss of neighboring podocytes, a compensatory response becomes necessary.
Functionally and structurally, the most important response to stress is podocyte hypertrophy. To undergo hypertrophy the podocyte needs to enter the S phase
of the cell cycle but keep the cell cycle arrest at the G1 or G2/M restriction point. This is ensured by p53-mediated induction of cyclin kinases, such as p21.
Mitogenic stimuli or DNA damage induce MDM2, which inactivates p53-mediated cell cycle arrest and forces the podocytes to complete mitosis. However,
podocytes need their actin cytoskeleton to maintain their sophisticated anatomical structure; therefore, this usually leads to an incomplete formation of
mitotic spindles, aberrant chromosome segregation, and/or podocyte detachment. In addition, podocytes cannot complete cytokinesis, which results in
aneuploid podocytes with two or more nuclei. Such cells are susceptible to death; hence, podocyte mitosis is not a sign of podocyte regeneration but
a pathologic mechanism of podocyte loss.
Mitotic Catastrophe in Podocytesquiescent cells reenter the G1 phase to increase the amount
of cell organelles and proteins. Although glomerular endo-
thelial cells and mesangial cells easily proliferate, podocytes
undergo hypertrophy, producing additional foot processes to
compensate for podocytopenia.2,44 But how do podocytes
undergo hypertrophy versus hyperplasia? The cell cycle can
be arrested in the G1 and G2 phases, at so-called restriction
points, which prevent podocyte progression to mitosis. Not
only is this fundamental control mechanism required for cell
hypertrophy, it also prevents aberrant mitosis of cells with
signiﬁcant DNA damage (Figure 1). However, if a cell with
defective DNA enters mitosis prematurely, before DNA
damage is repaired or before DNA replication is complete,
the subsequent aberrant mitosis leads to asymmetric chro-
mosomal division and formation of severely damaged cells,The American Journal of Pathology - ajp.amjpathol.orgprone to develop cancer. Most commonly, however, aber-
rant mitosis leads to cell death (ie, MC), a safeguard
mechanism to prevent cancer. Podocytes are not known to
form cancers, which supports the concept that podocytes
with signiﬁcant DNA damage cannot survive mitosis and, if
forced to override these cell cycle restriction points, detach
and are lost in the urine. Mitotic podocytes detach also
because actin assembly for forming the mitotic spindle is no
longer compatible with maintaining the cytoskeletal struc-
ture of secondary foot processes.45 Therefore, podocytes
may express cell cycle markers (such as Ki-67) when they
undergo hypertrophy, but they are unlikely to undergo
mitosis (ie, display nuclei in pro-, prometa-, meta-, ana-, or
telophase). Podocytes with mitotic ﬁgures are indeed sus-
ceptible to detachment and/or death (Figure 2).1367
Figure 2 Mitotic podocytes in human glomerular diseases. A: IgA nephropathy from 20-year-old woman with hematuria and necrotizing IgA. Mitotic
podocyte (arrow) among numerous detached counterparts (silver stain). B: Collapsing FSGS from a 54-year-old man with a protein level of 8.5 g/dL. Half
mitotic spindle in detached podocyte (arrow) in a glomerulus with implosion of the capillary loops (silver stain). C: Drug-induced MCD in an 84-year-old
woman with a protein level of 6 g/dL. Mitotic podocyte traveling toward the proximal tubule pole of the glomerulus (arrow) (H&E). Original magniﬁcation,
1000 (A and B); 400 (C).
Liapis et alMC in Glomerular Diseases
MC as a form of cell death was ﬁrst observed in the 1930s
in irradiated cancer tissues that had abnormal nuclear
conﬁgurations and spatial distribution of chromosomes.
Therefore, this type of cell death was called mitotic- or cell
divisioneassociated death.46e48 MC is heterogeneous at
least in carcinogenesis, characterized by molecular markers,
including cyclin B1edependent kinase Cdk1, pololike
kinases and aurora kinases, cell-cycle checkpoint proteins,
survivin, p53, caspases, and members of the Bcl-2 family.46
There are four different types: i) caspase independent; ii)
caspase dependent, which is the intermediate step to
apoptosis; iii) inducer of ploidy cycle, responsible for tumor
cell survival mechanism; and iv) the standalone subtype
of apoptosis.47,48 Podocytes in mitosis have not been as-
sessed systematically in proliferative glomerulonephritides.
However, most experienced renal pathologists have come
across an occasional podocyte in mitosis usually free ﬂoating
in the Bowman space (Figure 2). A single study by Nagata
et al49 reported one mitotic ﬁgure in a single podocyte in
a case of FSGS among 164 renal biopsy specimens with
glomerular disease. The examples shown in Figure 2, AeC,
are from patients with signiﬁcant proteinuria (necrotizing
IgA, collapsing glomerulopathy, and MCD, respectively).
Mitotic podocytes associated with proteinuria may be
a desperate but aborted attempt to regenerate epithelial
injury. Podocyte multinucleation on the other hand is
a recognized feature of aberrant mitosis.23,28 Nagata et al23
were intrigued by this phenomenon and reported it in 1998,
but the literature remained remarkably poor on this subject. In
lieu of the fact that aberrant mitosis and podocyte binuclea-
tion are synonymous to MC, we retrospectively reviewed
consecutive renal biopsy specimens in an exact number (nZ
164) as in the study by Nagata et al.23 We found twice as
many (n Z 12) multinucleated podocytes.3 All cases had
signiﬁcant proteinuria, and diagnoses included minimal
change, FSGS, IgA nephropathy, membranous nephropathy,
collapsing glomerulopathy, and membranoproliferative glo-
merulonephritis. Foot process effacement was invariably
present in association with binucleated podocytes.1368Binucleated podocytes are usually enlarged and reveal
cytoplasmic and nuclear changes. For example, nuclei may
appear edematous with one or more nucleoli (dotlike nuclear
chromatin condensation) (Figure 3C). Unusual features
include micronuclei, an indication of genomic instability and
a feature of MC (Figure 3D). In fact, micronuclei are thought
to derive from nuclear blebs.28 Cytoplasmic composition is
also altered in MC with increased number of organelles, such
asmitochondria and lipid droplets (Figure 3A) or cytoplasmic
vacuoles (Figure 3C). Sometimes, podocytes become tri-
nucleated (Figure 3C). It appears that MC is frequent in
injured podocytes that are forced to enter the cell cycle.
The classic example of mature podocytes reentering the cell
cycle is HIV-associated nephropathy (HIVAN), a type of
collapsing glomerulopathy (FSGS).
HIV-Associated Collapsing Glomerulopathy
Viral infection may trigger podocyte proliferation and cause
implosion (collapse) of capillary loops (Figure 4A). HIV
can infect podocytes (and parietal epithelial cells), leading to
podocyte mitosis and HIV nephropathy.50,51 Switch to
a proliferative podocyte phenotype is associated with loss of
mature podocyte markers, such as WT1 and p27, p57, cyclin
D1, cyclin A, and Ki-67 expression.22 Podocyte multi-
nucleation is a predominant feature of HIVAN previously
thought of as a compensatory mechanism of podocyte
repair.51,52 However, on the basis of our current under-
standing, it appears that virus-induced podocyte mitosis is
catastrophic, driving podocytes to cell death via MC.
Notably, these tightly packed podocytes pile up on top of
each other but to large extent remain attached to the GBM,
and there is no evidence of overt foot process effacement.
There is no evidence of apoptotic nuclear condensation.
Instead, podocytes are multinucleated, and the cytoplasm
appears fragile with cytoplasmic dense (osmiophilic) bodies
(lysosomes) (Figure 4, C and D). Eventually, these multi-
nucleated podocytes detach from the GBM, disrupt the
cytoplasm, and release the nucleus and cytoplasmic contents
into the Bowman space (Figure 4D). Multinucleated podo-
cytes are frequent in HIVAN (Figure 4, B and C), and actualajp.amjpathol.org - The American Journal of Pathology
Figure 3 Mitotic podocytes in human glomer-
ular diseases. A: IgA nephropathy. Hypertrophic,
binucleated podocyte with an increased number of
cytoplasmic organelles apparent on a renal biopsy
specimen from a 58-year-old patient with a creat-
inine level of 2.2 mg/dL and a protein level of 1.1
g/dL. B: Lupus membranous. Binucleated detached
podocyte apparent on a renal biopsy specimen
from a 31-year-old woman with a urinary protein
excretion of 4.2 g per 24 hours and a normal
creatinine level. C: FSGS. Trinucleated podocyte
apparent on a renal biopsy specimen from a 23-
year-old man with a protein level of 12.5 g/dL.
D: Recurrent FSGS. Micronucleolus next to podo-
cyte nucleus (arrow) is apparent on a transplant
renal biopsy specimen from a 23-year-old man with
a protein level of 12.3 g/dL.
Mitotic Catastrophe in Podocytespodocyte mitoses can be seen (Figure 2B). However, the
connection with MC and aberrant cell death is still vague
and little studied experimentally or clinically. For example,
a recent study found that 53BP1 aggregates in the nuclei of
HIV syncytia elicited by the HIV-1 envelope as a conse-
quence of nuclear fusion. Knockdown of 53BP1 induces
abnormal mitoses in HIV-1 envelopeeinduced syncytia,
leading to selective destruction through mitochondria-
dependent and caspase-dependent pathways. Thus, deple-
tion of 53BP1 triggers the demise of HIV-1eelicited syncytia
through MC.53 This suggests that new therapies that modify
MC cell death may hold promise as new HIVAN therapies.
Diabetic Glomerulosclerosis, Podocyte Hypertrophy,
and Progressive Glomerular Disease
Apoptosis is thought to be a major mechanism by which
podocytes die in diabetes and progressive glomerular dis-
ease.5e10,54 However, apoptotic cell death is rarely seen in
diabetic glomeruli in situ, despite numerous experimental
studies that provide biochemical evidence using transgenic
podocyte cell lines. In our experience (H.L.) with thousands
of renal biopsy specimens, we have not seen apoptotic
podocytes in renal biopsy specimens with diabetes. The
typical and diagnostic ﬁndings in advanced diabetes are
mesangial glomerulosclerosis and GBM thickening. Podo-
cytes invariably have foot process effacement and podocyte
hypertrophy with frequent detachment but no condensed
nuclei or nuclear fragmentation to suggest apoptosis; binu-
cleated podocytes are rarely seen (Figure 5A). Hypertrophic
podocytes in response to experimental mechanical injury are
an attempt to recover denuded GBM stretches left behind
from detached and lost podocytes.55 As previously described,The American Journal of Pathology - ajp.amjpathol.orghypertrophy represents cell cycle entry and arrest at the G2/
M phase.20 Podocyte hypertrophy is not infrequent in dia-
betic injury in humans, but whether this is a compensatory
mechanism that may trigger MC secondary to diabetes is
unknown. Studies on the pathology of podocyte death may be
an important parameter to evaluate in diabetes, particularly as
new therapies that target interception of MC and cell death
are advancing.3,45
MC Versus Other Forms of Podocyte Death
Necrotic Cell Death
This type of cell death is due to irreversible pathologic
extrinsic injury and is characterized by an increase in cell
volume due to edema (oncosis), cytoplasmic membrane
disruption, and loss of electron density in the cytoplasm. In
early stages, cytoplasmic organelles swell, and in late stages
the cell becomes leaky with plasma membrane blebs; the
nucleus also undergoes lysis. Because of plasma membrane
disintegration and organelle and nuclear dispersion, inﬂam-
mation ensues in the adjacent tissues. Necrosis is a manifes-
tation of severe acute injury, the result of direct or indirect
insults.56,57 Necrotic cell death was thought to be a passive
phenomenon, but meanwhile several inﬂammation-related
programmed forms of necrosis were described (caspase 1e
mediated proptosis and RIP-1 kinaseemediated necroptosis).
However, their role in podocyte loss is not deﬁned yet.58 The
example shown in Figure 5B is from a kidney transplant
patient with severe acute renal failure secondary to antibody
(C4d)emediated rejection, a type of endothelial injury that
may lead to hemorrhagic necrosis and glomerular throm-
bosis. Necrotizing glomerulonephritides may have similar
effects on podocytes.1369
Figure 4 Mitotic catastrophe in HIVAN. A:
Collapsing glomerulopathy from a 34-year-old man
who presented with acute renal failure; both
visceral and parietal podocytes are numerous,
proliferating over imploded capillary loops (silver
stain). B: On high magniﬁcation, gigantic, multi-
nucleated podocytes are apparent (arrow) (H&E).
C: Electron microscopy highlights even more
binucleated podocytes; podocytes also contain
numerous cytoplasmic osmiophilic vacuoles char-
acteristic of HIVAN. Podocytes are, however, still
attached to foot processes, attempting to main-
tain functionality perhaps but apparently unable
to divide. D: Podocyte death eventually ensues in
binucleated (arrows) HIV-infected podocytes.
Disintegrating cytoplasm and expulsion of cyto-
plasmic contents are shown. Original magniﬁca-
tion, 400 (A); 1000 (B).
Liapis et alAutophagic Podocyte Death
Autophagy is an evolutionarily conserved housekeeping
process in which cells acting in self-defense degrade their
cytoplasmic contents and eliminate protein aggregates and
damaged organelles.57,59 Three forms of autophagy are
recognized to date: macroautophagy, microautophagy, and
chaperone-mediated autophagy.59,60 The ﬁrst is the most
important and is characterized by sequestration of large
organelles, such as mitochondria and ribosomes within
a double membrane bound vacuole called the autophago-
some. The hallmark of autophagosomes is the presence of the
double-limiting membrane.60,61 The second form, micro-
autophagy, is characterized by entry of cytoplasmic mole-
cules and small organelles into lysosomes throughmembrane
invagination (Figure 5C). However, the different types of
autophagy do not operate in isolation but interact with each
other.59 Lysosomes are the ﬁnal destination of degraded
cytoplasmic waste in autophagosomes, and it is in this
capacity that lysosomes regulate organelle turnover by
autophagy.58e61 In postmitotic cells cytoplasmic waste
includes lipids and remnants of digested membranes that are
evident as loose threads inside lysosomes. Lipids can be
osmiophilic and stain dark on EM. Lipofuscin in aging cells is
one such dark staining lysosomal lipid. Lysosomes in contrast
to autophagosomes are bound by a single membrane.
However, at any given time, physiologically recycled cyto-
plasmic organelles may be found in transition from one state
to another, and their morphologic features can vary from
autophagosomes, transient vesicles, partially degraded lyso-
somes, to autophagic vacuoles. Precise deﬁnitions of the
various cytoplasmic vacuoles are beyond the scope of this
review and can be found in excellent authoritative litera-
ture.16,62 However, it should be mentioned that rough1370endoplasmic reticulum stress (Figure 5) is also present in
autophagic cell death after ischemic, toxic, immunologic, and
oxidative injuries and may trigger autophagy in renal
epithelial cells. The potential of modifying the course of
glomerular disease by understanding podocyte autophagy is
currently proposed. An obvious possibility is lysosomal
storage diseases, but little work has been performed in this
area.63,64 In random renal biopsy specimens, podocyte cyto-
plasmic vacuoles and lysosomes may represent routine
cytoplasmic debris removal and homeostatic maintenance.
Podocytes are indeed prone to constitutive autophagy as
a maintenance mechanism.65,66 Few studies on autophagy in
human renal disease are reported. For example, Sato et al67
examined renal biopsy specimens of 16 children with pro-
gressing IgA nephropathy; autophagy correlated with glo-
merulosclerosis, prompting the authors to suggest that lack of
complete cytoplasmic waste digestion infers podocyte cell
death and glomerulosclerosis. In animal models, the puro-
mycin aminonucleosideeinduced nephrosis demonstrates
that autophagy may affect podocytes in 2 ways: helping to
restore cytoplasmic podocyte integrity or, if excessive,
leading to direct podocyte cell death.13 How autophagy
proceeds to involve cytoplasmic organelles, including mito-
chondria, respiratory exchange ratio, the proteosome, and
lysosomes, remains to be resolved, but it seems that science is
fast evolving to link the various responses during autophagic
cell death by integrating molecular and structural podocyte
cell changes.68 Although autophagy is primarily a cytoplasm-
focused enterprise, recent studies suggest that nuclei may be
targeted as well. For example, micronuclei, a feature of MC,
can be subjected to autophagic removal, suggesting that
autophagy may have genome-stabilizing effects and thus may
also affect MC.69ajp.amjpathol.org - The American Journal of Pathology
Figure 5 A: Podocyte hypertrophy in diabetes. Advanced diabetic glomerulosclerosis shows thick capillary loops and mesangial sclerosis. Most podocytes
are hypertrophic and partially detached from the glomerular basement membrane (GBM); an occasional binucleated podocyte with decreased and condensed
cytoplasm possibly due to podocyte death via MC is apparent. B: Podocyte necrosis. Exploded podocyte in the Bowman space shows ruptured plasma
membrane, clear (edematous) nucleus, and dispersed cytoplasmic organelles apparent on a transplant renal biopsy specimen from a patient with severe acute
renal failure secondary to antibody-mediated rejection (EM). C: Podocyte autophagy. There are variably shaped, membrane-bound organelles; some have
double membrane (asterisk), and others have single membrane consistent with lysosomes or lysosomes in transition (autophagolysosomes) (thick arrows).
Dilated rough endoplasmic reticulum (thin arrow), a feature of autophagy, is also present in this renal biopsy specimen from a 56-year-old man with a urinary
protein excretion of 1 g per 24 hours (EM). D: Podocyte apoptosis. Detached podocytes have reduced volume and condensed and fragmented nuclei with
apoptotic bodies apparent on a renal biopsy specimen from a child with congenital nephrotic syndrome (diffuse mesangial sclerosis) and a urinary protein
excretion rate of 12 g per 24 hours (H&E). E: Detached viable podocyte. Detached podocyte with viable-appearing nucleus ﬂoats in the Bowman space adjacent
to parietal epithelial cells apparent on a renal biopsy specimen from a 7-year-old girl after bone marrow transplantation who presented with acute renal failure
(EM). Original magniﬁcation, 1500 (B and E); 5000 (C); 1000 (D).
Mitotic Catastrophe in PodocytesApoptotic Podocyte Death
Apoptosis is studied in various experimental glomerular
injuries. Most podocyte apoptosis data are derived from
in vitro experiments using transgenic cell lines. Morphologic
data of apoptotic podocytes are rarely presented.1 Instead,
biochemical assays of DNA fragmentation (TUNEL assay)The American Journal of Pathology - ajp.amjpathol.organd enzymatic (caspase) assays are consistently used and
interpreted as evidence of apoptosis. However, none of these
assays deﬁnitively distinguishes apoptosis from other types
of cell death. For example, in renal biopsy specimens with
FSGS, diabetes, or other glomerular diseases, apoptosis has
not been reported,1 but dozens of publications consider it1371
Liapis et ala given. It is possible that fragmented podocyte nuclei
disappear fast, but if apoptosis is a major mechanism of
podocyte cell death in situ, given the thousands of renal
biopsies performed, renal pathologists would have frequently
witnessed the phenomenon and reported it in the literature.
An exceptional example of an apoptotic podocyte in a renal
biopsy specimen is shown in Figure 5D. Apoptotic podocytes
have a densely stained nucleus and condensed eosinophilic
cytoplasm with characteristically shrunken cytoplasm and
nuclear fragmentation (apoptotic bodies). Lack of morpho-
logic evidence of apoptosis in experimental or human studies
has cast serious doubts on whether apoptosis is in fact
a common mechanism of podocyte loss in situ. Viable
podocytes with no signs of nuclear condensation are re-
covered from urine and grown in culture, suggesting that
detached podocytes from the GBM are not equivalent to dead
podocytes by apoptosis.70 In human renal biopsy specimens,
detached, viable-appearing podocytes ﬂoating free in the
Bowman space are occasionally seen (Figure 5E).
Is Foot Process Effacement in Minimal Change and
FSGS All We Should Be Looking For?
Both MCD and FSGS are common podocyte diseases diag-
nosed on EM by diffuse or focal foot process effacement,
respectively. Some authors consider them one disease in
a spectrum.1,18 Both can be diagnostically problematic on
renal biopsy specimens when foot process effacement is
minor in MCD or FSGS is absent on H&E because of
sampling error. Both may respond to steroids and, if resistant,
progress to glomerulosclerosis attributed to podocyte loss,
particularly in aggressive FSGS. The mechanism of podocyte
loss in FSGS is still debated. In situ podocytes loss in human
FSGS is thought to involve apoptosis but is not demon-
strated. If apoptosis were the pathway, then podocytes must
die before detachment. Animal models, for example, the
diphtheria toxineinduced FSGS, antieThy-1.1 nephritis, or
transforming growth factor b overexpression, suggest an
apoptotic cell death.5,11,12 Genetically engineered animals
also have coordinated signaling between slit diaphragm
proteins, such as nephrin (a cause of MCD and FSGS when
mutated), and structural cytoplasmic proteins synergistically
act to maintain nuclear and cytoplasmic integrity in podo-
cytes. Surprisingly, nephrin loss does not cause apoptosis,
implying that other molecules may compensate for nephrin
signaling.71 These and other studies have raised doubts about
podocyte apoptosis playing a role in hereditary and/or other
types of FSGS. Our recent work with Adriamycin-induced
FSGS documents that podocyte loss is driven by MDM2-
dependent MC becauseMDM2 degrades p53, which ensures
cell cycle arrest via induction of p21 and other cell cycle
regulators.3 Therefore, pharmacologic MDM2 inhibition
prevented MC of podocytes, which suppressed proteinuria
and prevented progressive glomerulosclerosis and subse-
quent tubulointerstitial disease. Taken together nuclear
abnormalities point to podocyte disease beyond foot process1372effacement. Binucleated cells or podocytes with micronuclei
or otherwise asymmetric nuclear divisions indicate aneu-
ploidy, implyingMC as a cause for podocyte loss, which may
not necessarily be targeted by steroids and requires alterna-
tive treatments to reinstate cell cycle arrest in podocytes.
Summary and Perspectives
Apoptosis and necrosis as forms of podocyte loss were
extensively discussed previously, but numerous other forms
of cell death exist. In view of the fact that apoptotic podocytes
are rarely spotted in human renal biopsy specimens and
podocyte necrosis may be limited to rare cases, it seems likely
that in most glomerular disorders podocyte loss involves yet
unknown or poorly characterized mechanisms. MC is one of
those poorly recognized forms of podocyte loss. Although
few studies have addressed MC in glomerular disease so far,
it appears that the best example of podocyte MC may yet be
HIVAN, where the promitotic effects of HIV DNA and HIV
proteins trigger podocyte loss and collapsing glomerulop-
athy. MC was also found to drive podocyte loss in experi-
mental Adriamycin nephropathy, which suggests that this
mechanism may also contribute to drug-induced FSGS in
humans. Currently, the relative contribution of MC to
podocyte loss in other forms of FSGS, in MCD, immune
complex glomerulonephritis, or other podocytopathies,
remains to be determined. MDM2 blockade is currently the
only therapeutic intervention reported to suppress podocyte
MC, but other cell cycleemodifying drugs are likely to have
similar effects. Given our limited knowledge about this
evolving topic, therapeutic targeting of MC in human pro-
teinuric glomerular disease remains speculative. Currently, it
becomes necessary that we examine which of the many forms
of cell death contribute to podocyte loss in vivo. This requires
a careful assessment of podocyte disease beyond foot process
effacement in the ﬁrst place.
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